INNOVATING TO ADDRESS UNMET NEEDS IN WOMEN’S HEALTH
HERE AT INEX INNOVATE,
WE KNOW THE ADVANCEMENT OF MEDICAL SCIENCE IS ONLY POSSIBLE WITH RIGOROUS STUDY AND INNOVATION.
Our founders and scientists work closely with professors, scientists and PhDs at leading research institutions such as A*STAR, IME, Singapore Bioimaging Consortium (SBIC), John Wayne Cancer Institute and the National University of Singapore (NUS) to conceptualise, research and develop new technologies in oncology, women’s and reproductive health.
INEX has particular expertise in translating research into molecular diagnostics, and applying new innovations into real-world clinical practice, specifically with the aim of addressing unmet needs in women's health. Over the past years, INEX has been granted patents from the United States, United Kingdom, Asia, and 27 countries in the EU.
RAPID COLOURIMETRIC ASSAY FOR INTRAOPERATIVE DETECTION OF OVARIAN CANCER
OvaCis is a globally patented intra-operative Point-Of-Care device that accurately discriminates benign from malignant epithelial ovarian cysts in 5 minutes with 98% accuracy.
With OvaCis, the diagnosis is performed on-the -spot in the operating theatre, unlike existing biopsies, which relies on tissue, takes up to 60 minutes, and has an accuracy of only 50-80%.
INEX is developing a next generation version, to be released in Q3 2020.
HIGHLY ACCURATE, MINIMALLY INVASIVE AND CONVENIENT WAY TO TEST PATIENTS FOR THE PRESENCE OF BREAST CANCER
NovoTect™ is a blood-based liquid biopsy test for the diagnosis of breast cancer based on the epigenetic differences between breast cancer and healthy individuals.
NovoTect™ is the first-ever test to stratify Asian patients regardless of sub-type and stage of breast cancer with high specificity and sensitivity. NovoTect™ has undergone multiple validation trials of 450+ patients with the latest results showing the upper range of test sensitivity is 97%, specificity 88% and positive predictive value 92%
FINDING THE HOLY GRAIL
INEX is a leader in the field of Fetal Cells in Maternal Blood (“FCMB”). FCMB is the technology of isolating fetal cells circulating in maternal blood with the objective of performing a variety of genomic diagnostic test on the target fetal cells. NIPD Assays with FCMB eliminates the chance of miscarriage, and is thought to be the holy grail in Prenatal Testing.With the successful cell isolation technology, high purity samples of fetal cells can be produced for clinical analysis and identification of over 7,000 genetic disorders, providing the full footprint of fetal genomics.
INEX has secured patents for a microfilter that can successfully isolate fetal cells from mother’s blood, and is one of only four experts globally focusing in the Non Invasive Prenatal Diagnostic (NIPD) field.
LEXI is expected to be launched by 2021.
AN INNOVATIVE EARLY DETECTION BLOOD TEST FOR OVARIAN CANCER
INEX has developed an innovative liquid biopsy test for the early detection of Ovarian Cancer, based on cell-free MicroRNA biomarkers.
The product has completed a Phase I clinical trial, with a study of 400 patients based on Asian populations, with demonstrable high accuracy in results. The Phase II patient study on over 600 samples is currently ongoing.
XENA is expected to be launched by 2021.